

Best Local Similarity 100.0%; Pred. No. 3e-06; Mismatches 0; Indels 0; Gaps 0;

Matches 15; Conservative 0;

Qy 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |
Db 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |

RESULT 2
AAB31319
ID AAB31319 standard; peptide; 15 AA.
XX
XX AAB31319;
XX
XX
XX 20-APR-2001 (first entry)
XX
XX Exemplary antigen characteristic of tumours and derived from MAGE-A3.
XX MAGE-A1; HLA; human leukocyte antigen; CD4+ T lymphocyte; cancer;
XX MAGE-A1 HLA class II-binding protein; vaccine.
XX
XX Homo sapiens.
XX
XX WO200078806-A1.
XX
XX 28-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016287.
XX
XX 18-JUN-1999; 99US-00336091.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Van Snick J, Lethe B, Chaux P, Boon-Palleur T, Van Der Bruggen P;
XX WPI; 2001-102698/11.
XX
XX Novel MAGE-A1 human leukocyte antigen class II peptides which bind to and
XX are presented to the class II molecules, useful for inducing immune
XX response and treating cancers characterized by expression of MAGE-A1.
XX
XX Disclosure; Page 32; 78pp; English.

AAB31302-59 represent exemplary antigens which are characteristic of
tumours. They can be used to enhance the immune response of vaccines
comprising peptides derived from human MAGE-A1 HLA (human leukocyte
antigen) class II-binding protein. Peptides derived from the MAGE-A1 HLA
binding protein stimulate the activity and proliferation of CD4+ T
lymphocytes. The MAGE-A1 HLA binding protein is useful as a diagnostic
agent for diagnosing a disorder characterized by expression of MAGE-A1.
The protein is used for treating a disorder characterized by expression
of MAGE-A1 such as cancers e.g. melanoma, squamous cell carcinomas,
colorectal carcinomas, osteosarcomas, and lymphocytic leukemias. Peptides
derived from the MAGE-A1 HLA binding protein are useful in the production
of anti-tumour vaccines

XX
XX
XX Sequence 15 AA;
SQ

Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |
Db 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |

RESULT 3
ABG79126
ID ABG79126 standard; peptide; 15 AA.
XX
XX AC ABG79126;
XX

DT 15-NOV-2002 (first entry)
XX
XX Human Mage-3 class II HLA tumour-restricted antigen peptide #1.
XX
XX Cell penetrating peptide; cancer; tumour; melanoma; thymoma; antigen;
XX lymphoma; sarcoma; lung cancer; non-Hodgkin's lymphoma; leukaemia;
XX Hodgkin's lymphoma; uterine cancer; cervical cancer; bladder cancer;
XX kidney cancer; adenocarcinoma; breast cancer; prostate cancer;
XX ovarian cancer; pancreatic cancer; epitope; vaccine; dendritic cell;
XX tumour infiltrating lymphocyte; TIL; human leukocyte antigen; HLA;
XX cytostatic; human.
XX
XX Homo sapiens.
XX
XX WO200264057-A2.
XX
XX 22-AUG-2002.
XX
XX 15-FEB-2002; 2002WO-US005212.
XX
XX 15-FEB-2001; 2001US-0268687P.
XX
XX (BAYU) BAYLOR COLLEGE MEDICINE.
XX
XX Wang R;
XX
XX WPI; 2002-627577/67.
XX
XX Novel composition for treating a disease in an animal, comprises an
XX immune effector cell and cell penetrating peptide associated with an
XX antigen or antibody.
XX
XX Disclosure; Page 21; 61pp; English.

XX The invention relates to a composition (I) comprising an immune effector
XX cell and a cell penetrating peptide (CPP) associated with an antigen or
XX antibody. Also included are (1) a vaccine comprising (I), CPP associated
XX with an antigen, and a pharmaceutically acceptable carrier and (2)
XX preparing a composition for a disease, by providing (I) and CPP
XX associated with an antigen for a disease, and introducing the antigen-
XX associated CPP to (I), where antigen enters into the cell. The antigens
XX are, for example, tumour antigen derived epitopes recognised by tumour
XX infiltrating lymphocytes (TIL) of HLA (human leukocyte antigen) class I
XX or II. The composition is useful for enhancing immunity in an animal to a
XX disease, by administering a mature dendritic cell comprising CPP
XX associated with an antigen to disease, to the animal, such that following
XX the administration, animal is protected from disease, where the animal
XX comprises both CD4+ and CD8+ T cells. It is also useful for treating a
XX disease (e.g. cancer, tumour, melanoma, thymoma, lymphoma, sarcoma, lung
XX cancer, non-Hodgkin's lymphoma, leukaemia, Hodgkin's lymphoma, uterine
XX cancer, cervical cancer, bladder cancer, kidney cancer, adenocarcinoma,
XX breast cancer, prostate cancer, ovarian cancer and pancreatic cancer).
XX The animal is further subjected to a cancer treatment including surgery,
XX radiation, chemotherapy or gene therapy. The administration of (I),
XX preferably dendritic cell is prior to, subsequent to or concurrent with,
XX the cancer treatment. The present sequence is a tumour antigen derived
XX epitope for inclusion in the composition of the invention

XX
XX
XX Sequence 15 AA;
SQ

Query Match 100.0%; Score 77; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 3e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |
Db 1 TSYVKVLHWMVKISG 15
| | | | | | | | | | | | | | | |

RESULT 4
AAG84641
ID AAG84641 standard; peptide; 15 AA.
XX
XX

Best Local Similarity 100.0%; Pred. NO. 1.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VFGLMEVDPIGHL 15
|||||

DB 1 VFGLMEVDPIGHL 15
|||||

RESULT 2
AAG84635
ID AAG84635 standard; peptide; 15 AA.
XX AAG84635;
DT 10-SEP-2001 (first entry)
XX MAGE3 DR supermotif binding peptide #46.
XX Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX cytostatic; immunostimulant.
XX Homo sapiens.
OS Synthetic.
XX WO200142267-A1.
PN 14-JUN-2001.
XX 11-DEC-2000; 2000WO-US033545.
XX 10-DEC-1999; 99US-00458298.
XX (EPIM-) EPIMUNE INC.
XX Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX Keogh E;
XX WPI; 2001-375002/39.
XX An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX the treatment and prevention of cancer.
XX Disclosure; Page 138; 171pp; English.

XX The present invention describes MAGE2/3 epitopes (I). Also described are:
XX (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX composition comprising (II), a unit dose of a peptide with at least 50
XX contiguous amino acids with 100% identity to the native peptide sequence
XX of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX cytostatic activity, and can be used in vaccines and as an
XX immunostimulant. A vaccine of (3) is useful for the treatment and
XX prevention of cancer. (I) is useful for monitoring or evaluating an
XX immune response by incubating a T-lymphocyte sample from a patient with
XX (I) that binds to an human leukocyte antigen (HLA) allele present in the
XX patient and detecting the presence of the T-lymphocyte that binds to the
XX peptide. The vaccine allows the opportunity to combine epitopes derived
XX from multiple tumour-associated molecules reducing the likelihood of
XX tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
XX represent amino acid sequences used in the exemplification of the present
XX invention

SQ Sequence 15 AA;
Query Match 100.0%; Score 78; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. NO. 1.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VFGLMEVDPIGHL 15
|||||

DB 1 VFGLMEVDPIGHL 15
|||||

RESULT 4
AAG84657

Best Local Similarity 100.0%; Pred. NO. 1.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VFGLMEVDPIGHL 15
|||||

DB 1 VFGLMEVDPIGHL 15
|||||

RESULT 4
AAG84657

DB 1 VFGLMEVDPIGHL 15

RESULT 3
AAG84605
ID AAG84605 standard; peptide; 15 AA.
XX AAG84605;
AC AAG84605;
DT 10-SEP-2001 (first entry)
XX MAGE3 DR supermotif binding peptide #16.

XX Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX cytostatic; immunostimulant.
XX Homo sapiens.
OS Synthetic.
XX WO200142267-A1.
PN 14-JUN-2001.
XX 11-DEC-2000; 2000WO-US033545.
XX 10-DEC-1999; 99US-00458298.
XX (EPIM-) EPIMUNE INC.
XX Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX Keogh E;
XX WPI; 2001-375002/39.
XX An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX the treatment and prevention of cancer.
XX Disclosure; Page 138; 171pp; English.

XX The present invention describes MAGE2/3 epitopes (I). Also described are:
XX (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX composition comprising (II), a unit dose of a peptide with at least 50
XX contiguous amino acids with 100% identity to the native peptide sequence
XX of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX cytostatic activity, and can be used in vaccines and as an
XX immunostimulant. A vaccine of (3) is useful for the treatment and
XX prevention of cancer. (I) is useful for monitoring or evaluating an
XX immune response by incubating a T-lymphocyte sample from a patient with
XX (I) that binds to an human leukocyte antigen (HLA) allele present in the
XX patient and detecting the presence of the T-lymphocyte that binds to the
XX peptide. The vaccine allows the opportunity to combine epitopes derived
XX from multiple tumour-associated molecules reducing the likelihood of
XX tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
XX represent amino acid sequences used in the exemplification of the present
XX invention

SQ Sequence 15 AA;
Query Match 87.2%; Score 68; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. NO. 8.4e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GIELMEVDPIGHL 15
|||||

DB 1 GIELMEVDPIGHL 13
|||||

RESULT 4
AAG84657

Best Local Similarity 100.0%; Pred. NO. 8.4e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GIELMEVDPIGHL 15
|||||

DB 1 GIELMEVDPIGHL 13
|||||

RESULT 4
AAG84657

Best Local Similarity 100.0%; Pred. NO. 8.4e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GIELMEVDPIGHL 15
|||||

DB 1 GIELMEVDPIGHL 13
|||||

RESULT 4
AAG84657

Best Local Similarity 100.0%; Pred. NO. 8.4e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GIELMEVDPIGHL 15
|||||

DB 1 GIELMEVDPIGHL 13
|||||

RESULT 4
AAG84657

Best Local Similarity 100.0%; Pred. No. 3.5e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 1 FFPVIFSKASSSLQL 15
|||||

Db 1 FFPVIFSKASSSLQL 15
|||||

RESULT 2
AAG84601
ID AAG84601 standard; peptide; 15 AA.

XX AC AAG84601;

XX DT 10-SEP-2001 (first entry)

XX DE MAGE3 DR supermotif binding peptide #12.

XX KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX cytotatic; immunostimulant.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200142267-A1.

XX PD 14-JUN-2001.

XX PF 11-DEC-2000; 2000WO-US033545.

XX PR 10-DEC-1999; 99US-00458298.

XX PA (EPIM-) EPIMUNE INC.

XX PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX PI Keogh E;

XX DR WPI; 2001-375002/39.

XX PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX the treatment and prevention of cancer.

XX PS Disclosure; Page 138; 171pp; English.

XX CC The present invention describes MAGE2/3 epitopes (I). Also described are:
XX (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX composition comprising (II), a unit dose of a peptide with at least 50
XX contiguous amino acids with 100% identity to the native peptide sequence
XX of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX cytostatic activity, and can be used in vaccines and as an
XX immunostimulant. A vaccine of (3) is useful for monitoring or evaluating an
XX immune response by incubating a T-lymphocyte sample from a patient with
XX the vaccine and detecting the presence of the T-lymphocyte that binds to the
XX peptide. The vaccine allows the opportunity to combine epitopes derived
XX from multiple tumour-associated molecules reducing the likelihood of
XX tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
XX represent amino acid sequences used in the exemplification of the present
XX invention

XX SQ Sequence 15 AA;

Query Match 100.0%; Score 71; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 FFPVIFSKASSSLQL 15
|||||

Db 1 FFPVIFSKASSSLQL 15

RESULT 3
AAG84602

XX ID AAG84602 standard; peptide; 15 AA.

XX AC AAG84602;

XX DT 10-SEP-2001 (first entry)

XX DE MAGE3 DR supermotif binding peptide #13.

XX KW Human; human leukocyte antigen; HLA epitope; cytotoxic T lymphocyte; CTL;
XX MAGE2; MAGE3; melanoma antigen gene; immune response; vaccine; cancer;
XX cytotatic; immunostimulant.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200142267-A1.

XX PD 14-JUN-2001.

XX PF 11-DEC-2000; 2000WO-US033545.

XX PR 10-DEC-1999; 99US-00458298.

XX PA (EPIM-) EPIMUNE INC.

XX PI Fikes J, Sette A, Sidney J, Southwood S, Chesnut R, Celis E;
XX PI Keogh E;

XX DR WPI; 2001-375002/39.

XX PT An isolated prepared MAGE2/3 epitope (I) for use in pharmaceuticals for
XX the treatment and prevention of cancer.

XX PS Disclosure; Page 138; 171pp; English.

XX CC The present invention describes MAGE2/3 epitopes (I). Also described are:
XX (1) a clonal cytotoxic T lymphocyte (CTL) that is cultured in vivo and
XX binds to a complex of (I); (2) a peptide (II) comprising (I) and a second
XX epitope and has less than 50 contiguous amino acids; (3) a vaccine
XX composition comprising (II), a unit dose of a peptide with at least 50
XX contiguous amino acids with 100% identity to the native peptide sequence
XX of MAGE2/3, and a pharmaceutical excipient; (4) an isolated nucleic acid
XX encoding (I); and (5) an isolated nucleic acid encoding (II). (I) has
XX cytostatic activity, and can be used in vaccines and as an
XX immunostimulant. A vaccine of (3) is useful for the treatment and
XX prevention of cancer. (I) is useful for monitoring or evaluating an
XX immune response by incubating a T-lymphocyte sample from a patient with
XX (I) that binds to a human leukocyte antigen (HLA) allele present in the
XX patient and detecting the presence of the T-lymphocyte that binds to the
XX peptide. The vaccine allows the opportunity to combine epitopes derived
XX from multiple tumour-associated molecules reducing the likelihood of
XX tumour escape due to antigen loss. AAG84515 to AAG84909 and AAB99725
XX represent amino acid sequences used in the exemplification of the present
XX invention

XX SQ Sequence 15 AA;

Query Match 91.5%; Score 65; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.6e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFPVIFSKASSSLQL 15
|||||

Db 1 FFPVIFSKASSSLQL 14

RESULT 4
AAG84629

ALIGNMENTS

1

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	78	100.0	15	12	US-10-149-135-2012
2	78	87.0	15	12	US-10-149-135-1982
3	66	84.6	15	12	US-10-149-135-2005
4	66	84.6	15	12	US-10-149-135-2034
5	66	84.6	15	12	US-10-149-135-2424
6	62	79.5	15	12	US-10-149-135-1987
7	62	79.5	15	12	US-10-149-135-2032
8	62	79.5	15	12	US-10-149-135-2425
9	62	79.5	15	12	US-10-149-135-2435
10	60	76.9	15	12	US-10-149-135-1997
11	60	76.9	15	12	US-10-149-135-2394
12	60	76.9	15	12	US-10-149-135-2408
13	58	74.4	11	12	US-10-149-135-307
14	58	74.4	11	12	US-10-149-135-667
15	56	71.8	15	12	US-10-149-135-1959

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being predicted and is derived by analysis of the total score distribution.

OTHER INFORMATION: Artificial Peptide
US-10-149-135-2012

Query Match 100.0%; Score 78; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.6e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VFGIELMEVDPIGHL 15
DB 1 VFGIELMEVDPIGHL 15

RESULT 2

US-10-149-135-1982
Sequence 1982, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE OF INVENTION: MAG2/3 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/189,702
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1982
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1982

Query Match 87.2%; Score 68; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.4e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3 GIELMEVDPIGHL 15
DB 1 GIELMEVDPIGHL 13
RESULT 3
US-10-149-135-2005
Sequence 2005, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE OF INVENTION: MAG2/3 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/189,702
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1982
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1982

Query Match 87.2%; Score 68; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.4e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GIELMEVDPIGHL 15
DB 1 GIELMEVDPIGHL 13

RESULT 3

US-10-149-135-2005
Sequence 2005, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE OF INVENTION: MAG2/3 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/189,702
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2034

APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE OF INVENTION: MAG2/3 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/189,702
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2005
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-2005

Query Match 84.6%; Score 66; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 7.7e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VFGIELMEVDPIG 13
DB 3 VFGIELMEVDPIG 15

RESULT 4

US-10-149-135-2034
Sequence 2034, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE OF INVENTION: MAG2/3 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
CURRENT FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/189,702
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2034

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:48:04 ; Search time 35.6667 Seconds
(without alignments)
132.025 Million cell updates/sec

Title: US-09-914-239-4

Perfect score: 71

Sequence: 1 PVPVIFSKASSSLQL 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1292805 seqs, 313927144 residues

Total number of hits satisfying chosen parameters: 214407

Minimum DB seq length: 0

Maximum DB seq length: 15

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:

- 1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/prodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /cgn2_6/prodata/1/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/prodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/prodata/1/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep.*
- 7: /cgn2_6/prodata/1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep.*
- 11: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep.*
- 12: /cgn2_6/prodata/1/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/prodata/1/pubpaa/US10_PUBCOMB.pep.*
- 14: /cgn2_6/prodata/1/pubpaa/US10_PUBCOMB.pep.*
- 15: /cgn2_6/prodata/1/pubpaa/US10_PUBCOMB.pep.*
- 16: /cgn2_6/prodata/1/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/prodata/1/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/prodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	71	100.0	15	12	US-10-149-135-1978
2	65	91.5	15	12	US-10-149-135-1979
3	62	87.3	15	12	US-10-149-135-2006
4	61	85.9	15	12	US-10-149-135-1923
5	59	83.1	15	12	US-10-149-135-2002
6	59	83.1	15	12	US-10-149-135-2393
7	59	83.1	15	12	US-10-149-135-2407
8	55	77.5	15	12	US-10-149-135-1924
9	54	76.1	15	12	US-10-149-135-2000
10	54	76.1	15	12	US-10-149-135-2392
11	54	76.1	15	12	US-10-149-135-2406
12	54	76.1	15	12	US-10-149-135-2434
13	52	73.2	15	12	US-10-149-135-1948
14	50	70.4	11	12	US-10-149-135-409
15	50	70.4	11	12	US-10-149-135-738

16	48	67.6	11	12	US-10-149-135-699	Sequence 699, App
17	48	67.6	11	12	US-10-149-135-1895	Sequence 1895, App
18	48	67.6	11	12	US-10-149-135-2256	Sequence 2256, App
19	46	64.8	9	12	US-10-149-135-1367	Sequence 1367, App
20	46	64.8	9	12	US-10-149-135-1534	Sequence 1534, App
21	46	64.8	10	12	US-10-149-135-1330	Sequence 1330, App
22	46	64.8	10	12	US-10-149-135-1562	Sequence 1562, App
23	46	64.8	11	12	US-10-149-135-1450	Sequence 1450, App
24	46	64.8	15	12	US-10-149-135-2013	Sequence 2013, App
25	44	62.0	9	12	US-10-149-135-2079	Sequence 2079, App
26	44	62.0	9	12	US-10-149-135-2137	Sequence 2137, App
27	44	62.0	10	12	US-10-149-135-1017	Sequence 1017, App
28	44	62.0	11	12	US-10-149-135-789	Sequence 789, App
29	44	62.0	11	12	US-10-149-135-1018	Sequence 1018, App
30	44	62.0	11	12	US-10-149-135-1096	Sequence 1096, App
31	43	60.6	10	12	US-10-149-135-446	Sequence 446, App
32	43	60.6	10	12	US-10-149-135-770	Sequence 770, App
33	42	59.2	8	12	US-10-149-135-1366	Sequence 1366, App
34	42	59.2	8	12	US-10-149-135-1533	Sequence 1533, App
35	42	59.2	8	12	US-10-149-135-1694	Sequence 1694, App
36	42	59.2	8	12	US-10-149-135-1790	Sequence 1790, App
37	42	59.2	9	12	US-10-149-135-1329	Sequence 1329, App
38	42	59.2	9	12	US-10-149-135-1661	Sequence 1661, App
39	42	59.2	9	12	US-10-149-135-1672	Sequence 1672, App
40	42	59.2	9	12	US-10-149-135-1857	Sequence 1857, App
41	42	59.2	9	12	US-10-149-135-2131	Sequence 2131, App
42	42	59.2	10	12	US-10-149-135-1449	Sequence 1449, App
43	42	59.2	10	12	US-10-149-135-1740	Sequence 1740, App
44	40	56.3	8	12	US-10-149-135-788	Sequence 788, App
45	40	56.3	8	12	US-10-149-135-829	Sequence 829, App

ALIGNMENTS

RESULT 1

US-10-149-135-1978
; Sequence 1978, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1978
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

OTHER INFORMATION: Artificial Peptide
US-10-149-135-1978

Query Match 100.0%; Score 71; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 15

RESULT 2

US-10-149-135-1979
Sequence 1979, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1979
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1979

Query Match 91.5%; Score 65; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

RESULT 3

US-10-149-135-2006
Sequence 2006, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1979
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1979

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

RESULT 4

US-10-149-135-1923
Sequence 1923, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1923
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1923

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

RESULT 5

US-10-149-135-2006
Sequence 2006, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1923
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-2006

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

RESULT 6

US-10-149-135-1979
Sequence 1979, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1923
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1979

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 2006
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-2006

Query Match 87.3%; Score 62; DB 12; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.00046;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FFPVIFSKASSL 13
Db 3 FFPVIFSKASSL 15

RESULT 4

US-10-149-135-1923
Sequence 1923, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1923
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-1923

Qy 1 FFPVIFSKASSL 13
Db 3 FFPVIFSKASSL 15

RESULT 5

US-10-149-135-2006
Sequence 2006, Application US/10149135
Publication No. US20040053822A1
GENERAL INFORMATION:
APPLICANT: Fikes, John
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celis, Esteban
TITLE OF INVENTION: Inducing Cellular Immune Responses to
FILE REFERENCE: 2060.0130001
CURRENT APPLICATION NUMBER: US/10/149,135
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: PCT/US00/33545
PRIOR FILING DATE: 2000-12-11
PRIOR APPLICATION NUMBER: US 09/458,298
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
NUMBER OF SEQ ID NOS: 2479
SOFTWARE: Patent in version 3.1
SEQ ID NO 1923
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Artificial Peptide
US-10-149-135-2006

Qy 2 FFPVIFSKASSLQL 15
Db 1 FFPVIFSKASSLQL 14

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-11

Perfect score: 81

Sequence: 1 VLHNMVKISGGPHIS 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA: *
1: /cgn2_6/ptodata/2/1aa/5A_COMB.pdp: *
2: /cgn2_6/ptodata/2/1aa/5B_COMB.pdp: *
3: /cgn2_6/ptodata/2/1aa/6A_COMB.pdp: *
4: /cgn2_6/ptodata/2/1aa/6B_COMB.pdp: *
5: /cgn2_6/ptodata/2/1aa/PCTUS_COMB.pdp: *
6: /cgn2_6/ptodata/2/1aa/backfiles.pdp: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	81	100.0	314	2	US-08-928-615-2
2	81	100.0	314	3	US-09-166-448-2
3	81	100.0	314	4	US-09-348-933-2
4	81	100.0	314	4	US-09-697-884-2
5	81	100.0	314	4	US-09-392-714-30
6	43	53.1	9	2	US-08-993-738A-12
7	43	53.1	9	4	US-09-241-268-12
8	43	53.1	9	4	US-09-495-562-12
9	43	53.1	132	4	US-09-134-001C-4209
10	43	53.1	475	4	US-09-252-991A-19146
11	43	53.1	624	4	US-09-252-991A-23659
12	41	50.6	144	4	US-09-621-976-5098
13	40	49.4	10	2	US-08-993-738A-9
14	40	49.4	10	2	US-08-713-354C-9
15	40	49.4	10	4	US-09-241-268-9
16	40	49.4	10	4	US-09-495-562-9
17	40	49.4	11	1	US-08-217-188A-61
18	40	49.4	11	1	US-08-687-226-61
19	40	49.4	11	3	US-08-667-725B-61
20	40	49.4	11	3	US-09-007-748-61
21	40	49.4	12	2	US-08-993-738A-5
22	40	49.4	12	2	US-09-036-582-32
23	40	49.4	12	3	US-09-183-708-36
24	40	49.4	12	3	US-08-713-354C-5
25	40	49.4	12	3	US-09-166-448-77
26	40	49.4	12	4	US-09-567-995-36
27	40	49.4	12	4	US-09-241-268-5

Sequence 32, Appl
Sequence 77, Appl
Sequence 5, Appl
Sequence 32, Appl
Sequence 6, Appl
Sequence 32, Appl
Sequence 38, Appl
Sequence 42, Appl
Sequence 40, Appl
Sequence 10, Appl
Sequence 31, Appl
Sequence 12098, A
Sequence 2, Appl
Sequence 28661, A
Sequence 6913, Ap
Sequence 9000, Ap
Sequence 22625, A

28 40 49.4 12 4 US-09-155-863-32
29 40 49.4 12 4 US-09-587-884-77
30 40 49.4 12 4 US-09-495-562-5
31 40 49.4 12 4 US-09-289-350-32
32 40 49.4 12 4 US-09-574-749B-6
33 40 49.4 12 4 US-09-318-141-32
34 40 49.4 12 4 US-09-169-717B-38
35 40 49.4 52 4 US-09-755-665-42
36 40 49.4 100 4 US-09-755-665-40
37 40 49.4 107 4 US-09-755-665-10
38 40 49.4 760 4 US-09-323-872A-31
39 40 49.4 760 4 US-09-072-433-35
40 49.4 765 4 US-09-489-039A-12098
41 35.5 48.8 382 3 US-09-142-551A-2
42 39 48.1 194 4 US-09-252-991A-28661
43 39 48.1 212 4 US-09-621-976-6913
44 39 48.1 216 4 US-09-489-039A-9000
45 39 48.1 327 4 US-09-252-991A-22625

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Strocobant, Vincent
; APPLICANT: Roon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; NUMBER OF INVENTIONS: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: 10461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2

Query Match 100.0%; Score 81; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VLHNMVKISGGPHIS 15
|||||


```

Db      286 VLHWMVKISGPHS 300

RESULT 2
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match      100.0%; Score 81; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VLHWMVKISGPHS 15
Db      286 VLHWMVKISGPHS 300

RESULT 3
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match      100.0%; Score 81; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VLHWMVKISGPHS 15
Db      286 VLHWMVKISGPHS 300

RESULT 4
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:

```

```

; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match      100.0%; Score 81; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VLHWMVKISGPHS 15
Db      286 VLHWMVKISGPHS 300

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/093927144
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,7144
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match      100.0%; Score 81; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VLHWMVKISGPHS 15
Db      286 VLHWMVKISGPHS 300

RESULT 6
US-08-993-738A-12
; Sequence 12, Application US/08993738A
; Patent No. 5928938
; GENERAL INFORMATION:
; APPLICANT: van der Bruggen, Pierre; DePlaen Etienne;
; APPLICANT: Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Peptides Which Complex With
; TITLE OF INVENTION: HLA-Cw*16 Molecules, and Uses Thereof

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-10

Perfect score: 77

Sequence: 1 TSYVKVLLHMKVKG 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
- 2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
- 3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
- 4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
- 5: /cgn2_6/ptodata/2/iaa/PTCUS_COMB.pep.*
- 6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	77	100.0	314	2	US-08-928-615-2
2	77	100.0	314	3	US-09-168-448-2
3	77	100.0	314	4	US-09-348-933-2
4	77	100.0	314	4	US-09-697-884-2
5	77	100.0	314	4	US-09-392-714-30
6	51	66.2	58	1	US-08-465-167A-1
7	51	66.2	58	4	US-08-627-820-1
8	51	66.2	309	1	US-08-465-167A-24
9	51	66.2	309	3	US-08-993-118-10
10	51	66.2	309	3	US-08-845-528C-10
11	51	66.2	309	4	US-08-627-820-24
12	51	66.2	309	4	US-09-066-281B-10
13	51	66.2	309	4	US-09-468-433C-10
14	51	66.2	309	4	US-09-392-714-29
15	43	55.8	413	4	US-09-215-694-6
16	42	54.5	632	4	US-09-853-533A-8
17	39	50.6	91	4	US-09-543-681A-4861
18	39	50.6	704	2	US-08-533-689A-17
19	39	50.6	704	4	US-09-183-861-17
20	39	50.6	704	4	US-09-022-765-17
21	39	50.6	704	4	US-09-551-974A-17
22	39	50.6	704	4	US-09-565-501A-17
23	39	50.6	704	4	US-09-639-206A-17
24	39	50.6	704	4	US-09-874-903-17
25	37	48.1	132	4	US-09-134-001C-4209
26	37	48.1	141	4	US-09-543-681A-4663
27	37	48.1	237	4	US-09-489-039A-12839

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535

GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Strobant, Vincent
; APPLICANT: Boom, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA: US/08/928,615
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441

INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Protein

US-08-928-615-2

Query Match 100.0%; Score 77; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 5.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TSYVKVLLHMKVKG 15
|||||

Sequence 1, Appl
Sequence 2, Appl
Sequence 2, Appl
Sequence 10089, A
Sequence 5432, Ap
Sequence 4128, Ap
Sequence 32, Appl
Sequence 26408, A
Sequence 5039, Ap
Sequence 3, Appl
Sequence 580, App
Sequence 3, Appl
Sequence 10, Appl
Sequence 2, Appl
Sequence 42, Appl
Sequence 585, App
Sequence 2, Appl
Sequence 4642, Ap

```

; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Val,rie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortbals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; PRIOR FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-697-884-2

Query Match 100.0%; Score 77; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 5.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TSYVKVLHHMVKISG 15
DB 281 TSYVKVLHHMVKISG 295

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O. Barbara
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseeng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-392-714-30

Query Match 100.0%; Score 77; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 5.7e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TSYVKVLHHMVKISG 15
DB 281 TSYVKVLHHMVKISG 295

RESULT 6
US-08-465-167A-1
; Sequence 1, Application US/08465167A
; Patent No. 5750395
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Livingston, Brian D.
; APPLICANT: Sette, Alessandro D.
; APPLICANT: Sidney, John C.

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-8
Perfect score: 74
Sequence: 1 GDNQIMPXAGLLIIV 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA: *
1: /cgn2_6/prodata/2/aaa/5A-COMB.pep: *
2: /cgn2_6/prodata/2/aaa/5B-COMB.pep: *
3: /cgn2_6/prodata/2/aaa/6A-COMB.pep: *
4: /cgn2_6/prodata/2/aaa/6B-COMB.pep: *
5: /cgn2_6/prodata/2/aaa/PCTUS-COMB.pep: *
6: /cgn2_6/prodata/2/aaa/backfiles1.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	74	100.0	314	2	US-08-928-615-2
2	74	100.0	314	3	US-09-166-448-2
3	74	100.0	314	4	US-09-348-933-2
4	74	100.0	314	4	US-09-697-884-2
5	74	100.0	314	4	US-09-392-714-30
6	66	89.2	309	1	US-08-465-167A-24
7	66	89.2	309	2	US-08-993-118-10
8	66	89.2	309	3	US-08-845-528C-10
9	66	89.2	309	4	US-08-627-820-24
10	66	89.2	309	4	US-09-066-281B-10
11	66	89.2	309	4	US-09-468-433C-10
12	66	89.2	309	4	US-09-392-714-29
13	47	63.5	11	1	US-08-687-226-67
14	46	62.2	11	1	US-08-217-188A-35
15	46	62.2	11	1	US-08-887-226-35
16	46	62.2	11	3	US-08-867-725B-35
17	46	62.2	11	3	US-09-007-748-35
18	44	59.5	10	3	US-08-159-339A-100
19	44	59.5	369	2	US-08-773-870-4
20	43	58.1	9	1	US-08-217-187-3
21	43	58.1	9	3	US-08-668-560-3
22	43	58.1	9	3	US-09-183-931-36
23	43	58.1	9	4	US-09-348-797-3
24	43	58.1	9	4	US-09-705-160-36
25	42	56.8	10	1	US-08-217-188A-34
26	42	56.8	10	1	US-08-687-226-34
27	42	56.8	10	3	US-08-667-725B-34

28	42	56.8	10	3	US-09-007-748-34	Sequence 34, Appl
29	42	56.8	1061	4	US-09-328-352-4445	Sequence 4445, Ap
30	39	52.7	673	4	US-09-352-991A-27111	Sequence 27111, A
31	39	52.7	787	4	US-09-352-991A-26468	Sequence 26468, A
32	39	52.7	1467	4	US-09-352-991A-17657	Sequence 17657, A
33	38	51.4	9	1	US-08-217-188A-33	Sequence 33, Appl
34	38	51.4	9	1	US-08-687-226-33	Sequence 33, Appl
35	38	51.4	9	3	US-08-667-725B-33	Sequence 33, Appl
36	38	51.4	9	3	US-09-007-748-33	Sequence 33, Appl
37	37	50.0	330	4	US-09-328-352-7359	Sequence 22, Appl
38	37	50.0	345	4	US-09-468-433C-22	Sequence 24124, A
39	37	50.0	390	4	US-09-252-991A-24124	Sequence 10044, A
40	37	50.0	1059	4	US-09-489-039A-10044	Sequence 26, Appl
41	36.5	49.3	407	4	US-09-468-433C-26	Sequence 80, Appl
42	36	48.6	96	3	US-08-946-329A-80	Sequence 14, Appl
43	36	48.6	273	3	US-08-928-213B-14	Sequence 4411, Ap
44	36	48.6	333	4	US-09-543-681A-4411	Sequence 5007, Ap
45	36	48.6	398	4	US-09-543-681A-5007	

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965935
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Protein
; US-08-928-615-2

Query Match 100.0%; Score 74; DB 2; Length 314;

Best Local Similarity 100.0%; Pred. No. 1.3e-05; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0

QY 1 GDNQIMPXAGLLIIV 15
|||||||

```
Db      191 GDNQIMPAGLLIIV 205

RESULT 2
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Strobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166.448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-166-448-2

Query Match      100.0%; Score 74; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GDNQIMPAGLLIIV 15
Db      191 GDNQIMPAGLLIIV 205

RESULT 3
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Strobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348.933
; PRIOR FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928.615
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-348-933-2

Query Match      100.0%; Score 74; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GDNQIMPAGLLIIV 15
Db      191 GDNQIMPAGLLIIV 205

RESULT 4
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Livingston, Brian D.
; APPLICANT: Sette, Alessandro D.
; APPLICANT: Sidney, John C.
```

```
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Strobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697.884
; PRIOR FILING DATE: 2000-10-27
; CURRENT APPLICATION NUMBER: 09/166.448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-697-884-2

Query Match      100.0%; Score 74; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GDNQIMPAGLLIIV 15
Db      191 GDNQIMPAGLLIIV 205

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392.714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; PRIOR FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-392-714-30

Query Match      100.0%; Score 74; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GDNQIMPAGLLIIV 15
Db      191 GDNQIMPAGLLIIV 205

RESULT 6
US-08-465-167A-24
; Sequence 24, Application US/08465167A
; Patent No. 5750395
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Livingston, Brian D.
; APPLICANT: Sette, Alessandro D.
; APPLICANT: Sidney, John C.
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-7
Perfect score: 82
Sequence: 1 PIGHLXIFATCGLS 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/2/iaa/5A COMB.pdp.*
2: /cgn2_6/ptodata/2/iaa/5B COMB.pdp.*
3: /cgn2_6/ptodata/2/iaa/6A COMB.pdp.*
4: /cgn2_6/ptodata/2/iaa/6B COMB.pdp.*
5: /cgn2_6/ptodata/2/iaa/PTUS COMB.pdp.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pdp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	82	100.0	314	2	US-08-928-615-2
2	82	100.0	314	3	US-09-166-448-2
3	82	100.0	314	4	US-09-348-333-2
4	82	100.0	314	4	US-09-697-884-2
5	82	100.0	314	4	US-09-392-714-30
6	60	73.2	309	1	US-08-465-167A-24
7	60	73.2	309	2	US-08-993-118-10
8	60	73.2	309	3	US-08-845-528C-10
9	60	73.2	309	4	US-08-627-820-24
10	60	73.2	309	4	US-08-261-160A-5
11	60	73.2	309	4	US-09-468-433C-10
12	60	73.2	309	4	US-09-392-714-29
13	53	64.6	10	3	US-08-159-339A-601
14	51	62.2	9	1	US-08-217-186-5
15	51	62.2	9	1	US-08-261-160A-5
16	51	62.2	9	2	US-08-290-381A-5
17	51	62.2	9	4	US-09-533-499B-5
18	51	62.2	11	1	US-08-217-188A-29
19	51	62.2	11	3	US-08-687-226-29
20	51	62.2	11	3	US-08-667-725B-29
21	51	62.2	11	3	US-09-007-748-29
22	45	56.1	10	1	US-08-186-266-20
23	45	54.9	596	4	US-09-489-039A-9470
24	43	52.4	10	3	US-08-159-339A-1213
25	43	52.4	369	2	US-08-773-870-4
26	42	51.2	9	1	US-08-186-266-17
27	42	51.2	9	3	US-08-159-339A-1214

28	41	50.0	9	1	US-08-217-188A-28	Sequence 28, Appl
29	41	50.0	9	1	US-08-687-226-28	Sequence 28, Appl
30	41	50.0	9	3	US-08-667-725B-28	Sequence 28, Appl
31	41	50.0	9	3	US-08-007-748-28	Sequence 28, Appl
32	41	50.0	147	1	US-08-284-003B-2	Sequence 2, Appl
33	41	50.0	147	2	US-08-959-865-3	Sequence 2, Appl
34	41	50.0	147	3	US-08-842-234-2	Sequence 3, Appl
35	41	50.0	147	4	US-09-671-317-488	Sequence 2, Appl
36	40	48.8	566	4	US-09-328-352-4809	Sequence 488, App
37	40	48.8	591	4	US-09-543-681A-5171	Sequence 4809, Ap
38	39	47.6	9	1	US-08-217-188A-30	Sequence 5171, Ap
39	39	47.6	9	1	US-08-687-226-30	Sequence 30, Appl
40	39	47.6	9	3	US-08-667-725B-30	Sequence 30, Appl
41	39	47.6	9	3	US-09-007-748-30	Sequence 30, Appl
42	39	47.6	482	4	US-09-328-352-6084	Sequence 6084, Ap
43	38	46.3	79	4	US-09-138-452A-1251	Sequence 1251, Ap
44	38	46.3	98	4	US-09-489-039A-7503	Sequence 7503, Ap
45	38	46.3	195	4	US-09-543-681A-4299	Sequence 4299, Ap

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Strobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: PastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2

Query Match 100.0%; Score 82; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. NO. 1.7e-06;
Matches 15; Conservative 0; Mismatches 0; Gaps 0;
OY 1 PIGHLXIFATCGLS 15
|||||

Db 171 PIGHLYIFATCLGLS 185

RESULT 2

US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortals, Jurgem
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match 100.0%; Score 82; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PIGHLYIFATCLGLS 15
Db 171 PIGHLYIFATCLGLS 185

RESULT 3

US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; PRIOR FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match 100.0%; Score 82; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PIGHLYIFATCLGLS 15
Db 171 PIGHLYIFATCLGLS 185

RESULT 4

US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortals, Jurgem
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

; APPLICANT: Chaux, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortals, Jurgem
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match 100.0%; Score 82; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PIGHLYIFATCLGLS 15
Db 171 PIGHLYIFATCLGLS 185

RESULT 5

US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; PRIOR FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match 100.0%; Score 82; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.7e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PIGHLYIFATCLGLS 15
Db 171 PIGHLYIFATCLGLS 185

RESULT 6

US-08-465-167A-24
; Sequence 24, Application US/08465167A
; Patent No. 5750395
; GENERAL INFORMATION:
; APPLICANT: Pikes, John D.
; APPLICANT: Livingston, Brian D.
; APPLICANT: Sette, Alessandro D.
; APPLICANT: Sidney, John C.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-6

Perfect score: 78

Sequence: 1 VFGIELMEVDPIGHL 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

- 1: /cgn2.6/prodata/2/1aa/5A-COMB.pep:*
- 2: /cgn2.6/prodata/2/1aa/5B-COMB.pep:*
- 3: /cgn2.6/prodata/2/1aa/6A-COMB.pep:*
- 4: /cgn2.6/prodata/2/1aa/6B-COMB.pep:*
- 5: /cgn2.6/prodata/2/1aa/PTUS-COMB.pep:*
- 6: /cgn2.6/prodata/2/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	78	100.0	314	2	US-08-928-615-2
2	78	100.0	314	3	US-09-166-448-2
3	78	100.0	314	4	US-09-348-933-2
4	78	100.0	314	4	US-09-697-884-2
5	78	100.0	314	4	US-09-392-714-30
6	74	94.9	16	2	US-08-928-615-6
7	74	94.9	16	3	US-09-166-448-6
8	74	94.9	16	4	US-09-348-933-6
9	74	94.9	16	4	US-09-697-884-6
10	57	73.1	369	2	US-08-773-870-4
11	53	67.9	309	1	US-08-465-167A-24
12	53	67.9	309	2	US-08-993-118-10
13	53	67.9	309	3	US-08-845-528C-10
14	53	67.9	309	4	US-08-827-820-24
15	53	67.9	309	4	US-09-066-281B-10
16	53	67.9	309	4	US-09-468-433C-10
17	53	67.9	309	4	US-09-392-714-29
18	51	65.4	380	2	US-08-773-870-5
19	49	62.8	10	1	US-08-796-883-17
20	49	62.8	10	2	US-09-036-582-5
21	49	62.8	10	2	US-08-531-864-17
22	49	62.8	10	3	US-08-502-506A-17
23	49	62.8	10	3	US-09-266-294-17
24	49	62.8	10	3	US-09-183-931-37
25	49	62.8	10	3	US-09-183-706-8
26	49	62.8	10	3	US-09-166-448-49
27	49	62.8	10	4	US-09-567-995-8

Sequence 37, Appl
Sequence 5, Appl
Sequence 49, Appl
Sequence 5, Appl
Sequence 5, Appl
Sequence 5, Appl
Sequence 11, Appl
Sequence 135, Appl
Sequence 29, Appl
Sequence 29, Appl
Sequence 4, Appl
Sequence 17, Appl
Sequence 2, Appl
Sequence 17, Appl
Sequence 51, Appl
Sequence 11, Appl
Sequence 23, Appl

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965335
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Strocobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: 10461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2

Query Match 100.0%; Score 78; DB 2; Length 314;

Best Local Similarity 100.0%; Fred. NO. 9.1e-07; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

QY 1 VFGIELMEVDPIGHL 15
|||||


```
Db      161 VFGIELMEVDPIGHL 175

RESULT 2
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match      100.0%; Score 78; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 9.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VFGIELMEVDPIGHL 15
Db      161 VFGIELMEVDPIGHL 175

RESULT 3
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match      100.0%; Score 78; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 9.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VFGIELMEVDPIGHL 15
Db      161 VFGIELMEVDPIGHL 175

RESULT 4
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match      100.0%; Score 78; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 9.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VFGIELMEVDPIGHL 15
Db      161 VFGIELMEVDPIGHL 175

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match      100.0%; Score 78; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 9.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VFGIELMEVDPIGHL 15
Db      161 VFGIELMEVDPIGHL 175

RESULT 6
US-08-928-615-6
; Sequence 6, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/08/928,615
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-928-615-6

Query Match      100.0%; Score 78; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 9.1e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VFGIELMEVDPIGHL 15
Db      161 VFGIELMEVDPIGHL 175
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-5
Perfect score: 70
Sequence: 1 SSLLQVFGIELMEVD 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA.*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	DB ID	Description
1	70	100.0	314	2	US-08-928-615-2
2	70	100.0	314	3	US-09-166-448-2
3	70	100.0	314	4	US-09-348-933-2
4	70	100.0	314	4	US-09-697-884-2
5	70	100.0	314	4	US-09-392-714-30
6	58	82.9	16	2	US-08-928-615-6
7	58	82.9	16	3	US-09-166-448-6
8	58	82.9	16	4	US-09-348-933-6
9	58	82.9	16	4	US-09-697-884-6
10	52	74.3	11	4	US-09-543-608A-24
11	50	71.4	309	2	US-08-465-167A-24
12	50	71.4	309	2	US-08-993-118-10
13	50	71.4	309	3	US-08-845-528C-10
14	50	71.4	309	4	US-08-627-820-24
15	50	71.4	309	4	US-09-066-281B-10
16	50	71.4	309	4	US-09-468-433C-10
17	50	71.4	309	4	US-09-392-714-29
18	50	71.4	380	2	US-08-773-870-5
19	47	67.1	10	4	US-08-197-484-83
20	47	67.1	10	4	US-08-197-484-142
21	47	67.1	10	4	US-09-543-608A-23
22	47	67.1	10	5	PCT-US95-02121-83
23	47	67.1	10	5	PCT-US95-02121-142
24	47	67.1	606	4	US-09-362-133A-6
25	45	64.3	11	1	US-08-217-188A-7
26	45	64.3	11	1	US-08-587-226-7
27	45	64.3	11	3	US-08-667-725B-7

28	45	64.3	11	3	US-09-007-748-7	Sequence 7, Appli
29	41	58.6	369	2	US-08-773-870-4	Sequence 4, Appli
30	41	58.6	1142	2	US-08-993-118-7	Sequence 7, Appli
31	41	58.6	1142	3	US-08-845-528C-7	Sequence 7, Appli
32	41	58.6	1142	3	US-09-061-709-2	Sequence 2, Appli
33	41	58.6	1142	4	US-09-066-281B-7	Sequence 7, Appli
34	41	58.6	1142	4	US-09-899-651-2	Sequence 2, Appli
35	41	58.6	1142	4	US-08-468-433C-7	Sequence 7, Appli
36	41	58.6	1142	4	US-09-392-714-26	Sequence 26, Appli
37	40	57.1	11	1	US-08-217-188A-25	Sequence 25, Appli
38	40	57.1	11	1	US-08-687-725B-25	Sequence 25, Appli
39	40	57.1	11	3	US-09-007-748-25	Sequence 25, Appli
40	40	57.1	10	1	US-08-217-188A-5	Sequence 5, Appli
41	39	55.7	10	1	US-08-687-226-5	Sequence 5, Appli
42	39	55.7	10	3	US-08-667-725B-5	Sequence 5, Appli
43	39	55.7	10	3	US-09-007-748-5	Sequence 5, Appli
44	39	55.7	10	3	US-09-183-931-32	Sequence 32, Appli
45	39	55.7	10	3	US-09-183-931-32	Sequence 32, Appli

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Strobant, Vincent
; APPLICANT: Soen, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-928-615-2

Query Match 100.0%; Score 70; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 SSLLQVFGIELMEVD 15
|||||

Db 156 SSLQLVFGIELMEVD 170

RESULT 2

US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortbals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match 100.0%; Score 70; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SSLQLVFGIELMEVD 15
Db 156 SSLQLVFGIELMEVD 170

RESULT 3

US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match 100.0%; Score 70; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SSLQLVFGIELMEVD 15
Db 156 SSLQLVFGIELMEVD 170

RESULT 4

US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre

; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortbals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match 100.0%; Score 70; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SSLQLVFGIELMEVD 15
Db 156 SSLQLVFGIELMEVD 170

RESULT 5

US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6686147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tsung
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match 100.0%; Score 70; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SSLQLVFGIELMEVD 15
Db 156 SSLQLVFGIELMEVD 170

RESULT 6

US-08-928-615-6
; Sequence 6, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-4
Perfect score: 71
Sequence: 1 PFPVIFSKASSLQ 15
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/2/iaa/5A-COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B-COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A-COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B-COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PTOUT-COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	71	100.0	314	2	US-08-928-615-2
2	71	100.0	314	3	US-09-166-448-2
3	71	100.0	314	4	US-09-348-933-2
4	71	100.0	314	4	US-09-397-884-2
5	71	100.0	314	4	US-09-392-714-30
6	51	71.8	309	1	US-08-465-167A-24
7	51	71.8	309	2	US-08-993-118-10
8	51	71.8	309	3	US-08-845-528C-10
9	51	71.8	309	4	US-08-627-820-24
10	51	71.8	309	4	US-09-066-281B-10
11	51	71.8	309	4	US-09-468-433C-10
12	51	71.8	309	4	US-09-392-714-29
13	42	59.2	15	3	US-08-159-339A-1217
14	42	59.2	15	3	US-08-159-339A-1215
15	41	57.7	1142	2	US-09-468-433C-22
16	41	57.7	1142	3	US-08-993-118-7
17	41	57.7	1142	3	US-08-845-528C-7
18	41	57.7	1142	3	US-09-061-709-2
19	41	57.7	1142	4	US-09-066-281B-7
20	41	57.7	1142	4	US-09-899-651-2
21	41	57.7	1142	4	US-09-468-433C-7
22	41	57.7	1142	4	US-09-392-714-26
23	39	54.9	9	3	US-08-159-339A-1220
24	39	54.9	2232	3	US-09-091-219-25
25	39	54.9	2232	4	US-09-660-541-25
26	39	54.9	2247	3	US-09-091-219-2
27	39	54.9	2247	4	US-09-660-541-2

Sequence 1207, Ap
Sequence 5831, Ap
Sequence 5, Appl
Sequence 4, Appl
Sequence 7772, Ap
Sequence 16, Appl
Sequence 12, Appl
Sequence 20, Appl
Sequence 20, Appl
Sequence 17191, A
Sequence 3418, A
Sequence 27, Appl
Sequence 27, Appl
Sequence 27, Appl
Sequence 25, Appl

38 53.5 10 3 US-08-159-339A-1207
38 53.5 60 4 US-09-621-976-5831
38 53.5 249 2 US-08-389-386-5
38 53.5 369 2 US-08-773-870-4
38 53.5 473 4 US-09-543-681A-7772
38 53.5 472 4 US-09-177-419C-2
37 52.1 314 4 US-09-362-336A-16
35 52.1 511 4 US-09-679-686B-12
35 50.7 368 2 US-08-869-137-2
36 50.7 383 4 US-09-627-650B-20
36 50.7 474 1 US-08-417-330A-20
35 49.3 121 4 US-09-352-991A-17191
35 49.3 121 4 US-09-134-000C-3418
35 49.3 126 2 US-08-702-105A-27
35 49.3 126 3 US-08-702-110A-27
35 49.3 126 3 US-09-325-571-27
35 49.3 126 4 US-09-848-585-27
35 49.3 127 2 US-08-702-105A-25

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chau, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: 10461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2

Query Match 100.0%; Score 71; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 PFPVIFSKASSLQ 15
|||||

```
Db      146 FFPVIFSKASSSLQL 160

RESULT 2
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match      100.0%; Score 71; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 FFPVIFSKASSSLQL 15
Db      146 FFPVIFSKASSSLQL 160

RESULT 3
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match      100.0%; Score 71; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 FFPVIFSKASSSLQL 15
Db      146 FFPVIFSKASSSLQL 160

RESULT 4
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Corthals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match      100.0%; Score 71; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 FFPVIFSKASSSLQL 15
Db      146 FFPVIFSKASSSLQL 160

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/09392714A
; Patent No. 6886147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,714A
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match      100.0%; Score 71; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 FFPVIFSKASSSLQL 15
Db      146 FFPVIFSKASSSLQL 160

RESULT 6
US-08-465-167A-24
; Sequence 24, Application US/08465167A
; Patent No. 5750395
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Livingston, Brian D.
; APPLICANT: Sette, Alessandro D.
; APPLICANT: Sidney, John C.
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-3

Perfect score: 85

Sequence: 1 GNWQYFFPVIFSKAS 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgm2_6/ptodata/2/iaa/5A_COMB.pep.*
- 2: /cgm2_6/ptodata/2/iaa/5B_COMB.pep.*
- 3: /cgm2_6/ptodata/2/iaa/6A_COMB.pep.*
- 4: /cgm2_6/ptodata/2/iaa/6B_COMB.pep.*
- 5: /cgm2_6/ptodata/2/iaa/PCTUS_COMB.pep.*
- 6: /cgm2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	85	100.0	314	2	US-08-928-615-2
2	85	100.0	314	3	US-09-166-448-2
3	85	100.0	314	4	US-09-348-933-2
4	85	100.0	314	4	US-09-697-884-2
5	85	100.0	314	4	US-09-392-714-30
6	77	90.6	15	3	US-08-159-339A-1215
7	62	72.9	10	3	US-08-159-339A-1218
8	56	65.9	9	3	US-08-159-339A-1217
9	49	57.6	9	3	US-08-465-167A-24
10	43	50.6	309	1	US-08-993-118-10
11	43	50.6	309	2	US-08-993-118-10
12	43	50.6	309	3	US-08-845-528C-10
13	43	50.6	309	4	US-08-627-820-24
14	43	50.6	309	4	US-09-066-281B-10
15	43	50.6	309	4	US-09-468-433C-10
16	43	50.6	309	4	US-09-392-714-29
17	42	49.4	440	4	US-09-252-991A-21718
18	42	49.4	724	3	US-08-793-331-4
19	42	49.4	725	3	US-08-793-331-6
20	41	48.2	46	1	US-08-118-270-199
21	41	48.2	46	5	PCT-US93-08528-199
22	41	48.2	369	2	US-08-773-870-4
23	41	48.2	772	4	US-09-907-794A-339
24	41	48.2	772	4	US-09-905-125A-339
25	41	48.2	772	4	US-09-902-775A-339
26	40.5	47.6	171	4	US-09-489-039A-9991
27	40	47.1	823	1	US-07-745-206A-15

Sequence 15, Appl
Sequence 13, Appl
Sequence 13, Appl
Sequence 48, Appl
Sequence 8, Appl
Sequence 10, Appl
Sequence 36, Appl
Sequence 10, Appl
Sequence 2, Appl
Sequence 2, Appl
Sequence 47, Appl
Sequence 6, Appl
Sequence 4, Appl
Sequence 35, Appl
Sequence 590, Ap
Sequence 7281, Ap
Sequence 16, Appl

ALIGNMENTS

RESULT 1
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAG-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2

Query Match 100.0%; Score 85; DB 2; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GNWQYFFPVIFSKAS 15

|||||

```
Db      141 GNWQYFFPVIFSKAS 155

RESULT 2
US-09-166-448-2
; Sequence 2, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-2

Query Match      100.0%; Score 85; DB 3; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GNWQYFFPVIFSKAS 15
Db      141 GNWQYFFPVIFSKAS 155

RESULT 3
US-09-348-933-2
; Sequence 2, Application US/09348933
; Patent No. 6359211
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-2

Query Match      100.0%; Score 85; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GNWQYFFPVIFSKAS 15
Db      141 GNWQYFFPVIFSKAS 155

RESULT 4
US-09-697-884-2
; Sequence 2, Application US/09697884
; Patent No. 6426217
; GENERAL INFORMATION:
; APPLICANT: Chauv, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortals, Jurgan
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-2

Query Match      100.0%; Score 85; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GNWQYFFPVIFSKAS 15
Db      141 GNWQYFFPVIFSKAS 155

RESULT 5
US-09-392-714-30
; Sequence 30, Application US/093927144
; Patent No. 6886147
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Gure, Ali O.
; APPLICANT: Williamson, Barbara
; APPLICANT: Chen, Yao-Tseng
; APPLICANT: Old, Lloyd J.
; TITLE OF INVENTION: Cancer Associated Antigens and Uses
; FILE REFERENCE: L0461/7062
; CURRENT APPLICATION NUMBER: US/09/392,7144
; CURRENT FILING DATE: 1999-09-09
; EARLIER APPLICATION NUMBER: PCT/US98/14679
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 314
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-392-714-30

Query Match      100.0%; Score 85; DB 4; Length 314;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GNWQYFFPVIFSKAS 15
Db      141 GNWQYFFPVIFSKAS 155

RESULT 6
US-08-159-339A-1215
; Sequence 1215, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 17, 2004, 17:19:33 ; Search time 11.7778 Seconds
(without alignments)
65.750 Million cell updates/sec

Title: US-09-914-239-2

Perfect score: 74

Sequence: 1 RKVAELVHFLLLKYR 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA.*
1: /cgn2_6/ptodata/2/iaa/5A.COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B.COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A.COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B.COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/6CTUS.COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/6CTUS.COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	74	100.0	16	2	US-08-928-615-3
2	74	100.0	16	3	US-08-928-615-3
3	74	100.0	16	4	US-08-928-615-3
4	74	100.0	16	4	US-08-928-615-3
5	74	100.0	314	2	US-08-928-615-2
6	74	100.0	314	3	US-08-928-615-2
7	74	100.0	314	4	US-08-928-615-2
8	74	100.0	314	4	US-08-928-615-2
9	74	100.0	314	4	US-08-928-615-2
10	64	86.5	14	3	US-08-928-615-3
11	64	86.5	14	4	US-08-928-615-3
12	64	86.5	15	3	US-08-928-615-2
13	64	86.5	15	4	US-08-928-615-2
14	64	86.5	16	3	US-08-928-615-3
15	64	86.5	16	4	US-08-928-615-3
16	60	81.1	13	3	US-08-928-615-3
17	60	81.1	13	4	US-08-928-615-3
18	60	81.1	14	3	US-08-928-615-2
19	60	81.1	14	4	US-08-928-615-2
20	60	81.1	15	3	US-08-928-615-3
21	60	81.1	15	4	US-08-928-615-3
22	58	78.4	309	1	US-08-928-615-3
23	58	78.4	309	2	US-08-928-615-3
24	58	78.4	309	3	US-08-928-615-3
25	58	78.4	309	4	US-08-928-615-3
26	58	78.4	309	4	US-08-928-615-3
27	58	78.4	309	4	US-08-928-615-3

28	58	78.4	309	4	US-09-392-714-29	Sequence 29, Appl
29	57	77.0	346	4	US-09-468-433C-22	Sequence 22, Appl
30	56	75.7	12	2	US-08-928-615-9	Sequence 9, Appl
31	56	75.7	12	3	US-09-166-448-9	Sequence 9, Appl
32	56	75.7	12	4	US-09-348-933-9	Sequence 9, Appl
33	56	75.7	12	4	US-09-697-884-9	Sequence 9, Appl
34	56	75.7	13	3	US-09-166-448-31	Sequence 31, Appl
35	56	75.7	13	4	US-09-697-884-31	Sequence 31, Appl
36	56	75.7	14	3	US-09-166-448-30	Sequence 30, Appl
37	56	75.7	14	4	US-09-697-884-30	Sequence 30, Appl
38	56	75.7	16	2	US-08-928-615-4	Sequence 4, Appl
39	56	75.7	16	3	US-09-166-448-4	Sequence 4, Appl
40	56	75.7	16	4	US-09-348-933-4	Sequence 4, Appl
41	56	75.7	16	4	US-09-697-884-4	Sequence 4, Appl
42	56	75.7	373	4	US-09-066-251B-19	Sequence 19, Appl
43	56	75.7	373	4	US-09-468-433C-19	Sequence 19, Appl
44	51	68.9	10	3	US-08-159-339A-1206	Sequence 1206, Ap
45	51	68.9	10	3	US-09-166-448-41	Sequence 41, Appl

ALIGNMENTS

RESULT 1
US-08-928-615-3
; Sequence 3, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: Chaux, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/POCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-928-615-3

Query Match 100.0%; Score 74; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RKVAELVHFLLLKYR 15
|||||


```
Db      1 RKVAELVHFLLLKYR 15

RESULT 2
US-09-166-448-3
; Sequence 3, Application US/09166448
; Patent No. 6291430
; GENERAL INFORMATION:
; APPLICANT: ChauX, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortbals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/166,448
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-166-448-3

Query Match      100.0%; Score 74; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RKVAELVHFLLLKYR 15
Db      1 RKVAELVHFLLLKYR 15

RESULT 3
US-09-348-933-3
; Sequence 3, Application US/09348933
; Patent No. 6369211
; GENERAL INFORMATION:
; APPLICANT: ChauX, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7065
; CURRENT APPLICATION NUMBER: US/09/348,933
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: US 08/928,615
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-348-933-3

Query Match      100.0%; Score 74; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RKVAELVHFLLLKYR 15
Db      1 RKVAELVHFLLLKYR 15

RESULT 4
US-09-697-884-3
; Sequence 3, Application US/09697884
; Patent No. 6428217
; GENERAL INFORMATION:
```

```
; APPLICANT: ChauX, Pascal
; APPLICANT: Vantomme, Valrie
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon-Falleur, Thierry
; APPLICANT: van der Bruggen, Pierre
; APPLICANT: Thielemans, Kris
; APPLICANT: Cortbals, Jurgen
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES
; FILE REFERENCE: L0461/7052
; CURRENT APPLICATION NUMBER: US/09/697,884
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: 09/166,448
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-697-884-3

Query Match      100.0%; Score 74; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RKVAELVHFLLLKYR 15
Db      1 RKVAELVHFLLLKYR 15

RESULT 5
US-08-928-615-2
; Sequence 2, Application US/08928615
; Patent No. 5965535
; GENERAL INFORMATION:
; APPLICANT: ChauX, Pascal
; APPLICANT: Stroobant, Vincent
; APPLICANT: Boon, Thierry
; APPLICANT: van der Bruggen, Pierre
; TITLE OF INVENTION: MAGE-3 PEPTIDES PRESENTED
; TITLE OF INVENTION: BY HLA CLASS II MOLECULES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02210-2211
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/928,615
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: L0461/7017
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 314 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-928-615-2
```